secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2022-07-27T23:59:59+00:00
Accession:  0000950142-22-002314
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics appoints Paul Sekhri as President and CEO effective August 1, 2022
--------------------------------------------------------------------------------

- Paul Sekhri appointed President and CEO effective Aug 1, 2022; succeeds Richard Nelson, who becomes EVP and remains on board.
- Employment terms: $480k base salary, 75% bonus target, 2.2M stock options at $0.79/share (NASDAQ inducement grant).
- Options vest 25% after one year, then quarterly over three years; accelerated vesting on certain performance metrics.
- Severance: 12 months base (18 months post-change of control), COBRA, target bonus; two-year non-compete and non-solicit.
- vTv is preparing Phase 3 trials for TTP399 (type 1 diabetes) with recent $25M G42 investment and Breakthrough Therapy designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/0000950142-22-002314-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000095014222002314/eh220274048_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-002314

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer